Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89,560 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TREAT Clear all
Completed Not applicable Interventional Accepts healthy volunteers

rPMS and Radiofrequency for Abdominal Toning and Reduction of Subcutaneous Fat

NCT04587986
View directory record Official record
Conditions
Fat Burn
Interventions
BTL-899
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
River Bluff, Kentucky • Hunt Valley, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 6, 2026, 7:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTO-201 in Acute Otitis Externa

NCT02801370
View directory record Official record
Conditions
Acute Otitis Externa, Swimmer's Ear
Interventions
12 mg ciprofloxacin, Sham Control
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

NCT04402970
View directory record Official record
Conditions
SARS-CoV 2, ARDS
Interventions
Dornase Alfa Inhalation Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 6, 2026, 7:34 AM EDT
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 2 Interventional

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

NCT04343573
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

NCT01764269
View directory record Official record
Conditions
Fever
Interventions
text message surveillance for fever
Other
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 59 Months
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional Results available

Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy

NCT02819973
View directory record Official record
Conditions
Sudden Cardiac Death, Heart Failure
Interventions
Educational Video1, Educational Video 2, Usual Care 3
Other
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 6, 2026, 7:34 AM EDT
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

NCT00074269
View directory record Official record
Conditions
Breast Cancer
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 6, 2026, 7:34 AM EDT
Enrolling by invitation Not applicable Interventional

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

NCT07061769
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
Interventions
SHIFT
Device
Lead sponsor
FluxWear, INC
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

NCT04583969
View directory record Official record
Conditions
COVID-19
Interventions
Lenzilumab, Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional

Comparison of School-Based Supervised Versus Parental Supervised Asthma Therapy

NCT00110383
View directory record Official record
Conditions
Asthma
Interventions
School-Based Supervised Asthma Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 12 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair

NCT02036983
View directory record Official record
Conditions
Bilateral Inguinal Hernia Repair
Interventions
Transversus abdominis plane block (TAP BLOCK), Instillation of surgical site with local anesthetic., Opioid IV medications (Control)
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

NCT00089583
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
LEXIVA (GW433908), Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 6, 2026, 7:34 AM EDT
Withdrawn Phase 2 Interventional

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Diagnostic Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional

PRISM for Depression and Anxiety in Young Adults With Cancer

NCT06502483
View directory record Official record
Conditions
Cancer Diagnosis, Non-Metastatic Neoplasm, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Depression, Anxiety, Desmoid
Interventions
Promoting Resilience in Stress Management Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional Results available

The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis

NCT00490841
View directory record Official record
Conditions
Renal Artery Obstruction, Hypertension, Renal
Interventions
Herculink Elite Renal Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Paclitaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Rizatriptan Prescribing Portions for Treatment of Migraine

NCT00397254
View directory record Official record
Conditions
Migraine
Interventions
rizatriptan
Drug
Lead sponsor
Clinvest
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Diamond Bar, California • San Francisco, California • Oviedo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Sep 6, 2026, 7:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954
View directory record Official record
Conditions
Edentulous Alveolar Ridge
Interventions
Gintuit, Bio-Gide
Biological · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 6, 2026, 7:34 AM EDT
Completed Not applicable Interventional

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

NCT00002354
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 7:34 AM EDT
Active, not recruiting Phase 2 Interventional

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

NCT04607954
View directory record Official record
Conditions
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
Interventions
Durvalumab, Lurbinectedin
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 6, 2026, 7:34 AM EDT